CPI-613 | 9464

CPI-613 is a non-redox active lipoate derivative that acts as a selective inhibitor mitochondrial enzymes pyruvate dehydrogenase (PDH) and α-ketoglutarate dehydrogenase. In vitro, CPI-613 dose-dependently and efficiently kills H460 human lung cancer cells and Saos-2 human sarcoma cells. In vitro, CPI-613 treatment potently disrupts H460 cancer cell mitochondrial metabolism including inhibition of PDH complex activity. CPI-613 treatment also leads to loss of mitochondrial membrane potential as assessed by JC-1 mitochondrial uptake. CPI-613 also induces apoptotic and non-apoptotic cell death in the cells of H460 human lung cancer and Saos-2 human sarcoma in vitro.

CPI-613 is a non-redox active lipoate derivative that acts as a selective inhibitor mitochondrial enzymes pyruvate dehydrogenase (PDH) and α-ketoglutarate dehydrogenase. In vitro, CPI-613 dose-dependently and efficiently kills H460 human lung cancer cells and Saos-2 human sarcoma cells. In vitro, CPI-613 treatment potently disrupts H460 cancer cell mitochondrial metabolism including inhibition of PDH complex activity. CPI-613 treatment also leads to loss of mitochondrial membrane potential as assessed by JC-1 mitochondrial uptake.

9464 | CPI-613 DataSheet

Alternate Name/Synonyms: 6,8-Bis[(phenylmethyl)thio]octanoic acid

Appearance: White solid

Formulation: N/A

CAS Number: 95809-78-2

Structure Available?: Yes

Peptide sequence: N/A

Salt Form: N/A

Molecular Formula: C₂₂H₂₈O₂S₂

Molecular Weight: 388.59

Cell-Permeable?: Yes

Purity: ≥98% by HPLC

Solubilities: DMSO (>30 mg/ml) or EtOH (>20 mg/ml)

Handling: Protect from air and light

Country of Origin: USA

Tag Line: A selective pyruvate dehydrogenase (PDH) inhibitor

MDL Number: MFCD22420826

PubChem CID: 24770514

SMILES: C1=CC=C(C=C1)CSCCC(CCCCC(=O)O)SCC2=CC=CC=C2

InChi: InChI=1S/C22H28O2S2/c23-22(24)14-8-7-13-21(26-18-20-11-5-2-6-12-20)15-16-25-17-19-9-3-1-4-10-19/h1-6,9-12,21H,7-8,13-18H2,(H,23,24)

InChi Key: ZYRLHJIMTROTBO-UHFFFAOYSA-N